The emerging role of pharmacogenomic testing is a critical part of personalized medicine practices which examines how deoxyribonucleic acid (DNA) affects an individual response to medications. In most cases, DNA can determine whether the individual may experience adverse reactions as well as the likelihood of the medication's effectiveness and overall safety. While currently applied to only a limited number of conditions and medications such as HIV, certain cancers, depression and heart disease, the field of pharmacogenomic testing is rapidly expanding and being embraced by the healthcare industry as a whole.
No takes yet. Share an insight, caveat, or question.
Leigh Davitian (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: